Cefalexin monohydrate is incorporated into companion animal oral solid dosage forms at high drug loadings where direct compression is rarely viable because of poor bulk flow and high dose-to-tablet mass ratio. A representative core for a 600 mg cefalexin tablet contains 630 mg cefalexin monohydrate in a 750 mg core, corresponding to 84% w/w cefalexin monohydrate; lower strengths such as 75 mg, 150 mg, and 300 mg use proportionally reduced active loads with a microcrystalline cellulose and lactose monohydrate filler system. Finished tablet hardness is maintained between 80 N and 120 N, friability below 1.0% according to USP <1216>, and disintegration time below 15 min in 0.1 M hydrochloric acid at 37 °C per USP <701>. API batch release is aligned with the Ph. Eur. Cefalexin monohydrate monograph and the USP Cephalexin monograph; residual solvent control follows VICH GL18, and microbial limits for non-sterile oral powders are tested under Ph. Eur. 5.1.4.

Wet granulation is preferred over direct compression because cefalexin monohydrate is a crystalline, high-dose active with poor bulk flow characteristics, and compression pressure above approximately 25 kN on a rotary press can induce capping. The active is pre-sieved through a 0.5 mm screen and granulated in a high-shear granulator with povidone K30 at 2–4% w/w as binder; purified water is sprayed at 3–5% w/w of dry charge while impeller speed is held at 200–300 rpm and chopper speed at 1500–2500 rpm for 2–4 min. Drying in a fluid-bed dryer with inlet air set to 55–65 °C continues until loss on drying reaches 1.5–2.5% w/w; the granulate is milled through a 0.8 mm screen, then blended with crospovidone 2–4% w/w and magnesium stearate 0.5–1.0% w/w. Direct capsule filling on an automatic dosator or tamping-pin machine requires granule bulk density between 0.55 g/mL and 0.70 g/mL; batch-to-batch bulk density drift above this range causes die fill variation and individual mass uniformity failures under USP <905>. Aqueous film coating using a PVA/PEG-based ready-mix is applied to mask the bitter taste and to reduce dusting; coating pan bed temperature is held below 50 °C to avoid dehydration of the monohydrate and an associated dissolution shift. Released product consists of film-coated tablets of 75 mg, 150 mg, 300 mg, and 600 mg cefalexin, and hard gelatin or HPMC capsules of 250 mg and 500 mg.

What Reconstitution pH Range Prevents Cefalexin Monohydrate Caking in Flavoured Veterinary Suspension Vehicles?

For oral suspension dry powders, cefalexin monohydrate is dispersed in a dry granule matrix containing sucrose, xanthan gum, colloidal silicon dioxide, and a citric acid/sodium citrate buffer. The active is incorporated to provide 125 mg/5 mL or 250 mg/5 mL after reconstitution with potable water; the dry powder contains 13–19% w/w cefalexin monohydrate because the bulk of the vehicle is soluble carbohydrate. The buffering system holds the reconstituted suspension between pH 3.5 and 5.5, a range in which cefalexin monohydrate remains chemically stable during the assigned refrigerated beyond-use period and in which the suspending agent hydrates without over-viscosity. Wet granulation with ethanol or an ethanol-water mixture produces free-flowing granules; drying is conducted below 45 °C to prevent degradation and to protect flavour components. The dried granules are filled into amber HDPE bottles with a desiccant-free cap; after reconstitution, the product is stored at 2–8 °C for a maximum of 14 days. Sedimentation volume at 24 h should remain above 0.90, and redispersibility after storage should require no more than 15 inversions. Viscosity is measured with a Brookfield rotational viscometer at 25 °C; if the spindle reading falls outside the validated range after reconstitution, the bottle is rejected because subsequent dose uniformity cannot be assured under USP <905> and Ph. Eur. 5.1.4.

Antimicrobial preservative effectiveness is evaluated according to USP <51> using the compendial challenge organisms; because cefalexin is itself antibacterial, preservative efficacy testing is run with the active present to avoid over-conserving the formulation. The powder blend is tested for loss on drying below 1.5% w/w to prevent lactose-catalysed browning during shelf storage and for blend uniformity using Ph. Eur. 2.9.40; an acceptance value below 15 is required before fill weight is locked. Filling of multi-dose bottles is performed on an auger powder filler under relative humidity below 40% RH because cefalexin monohydrate can become tacky and bridge in the hopper if the processing environment exceeds the validated humidity boundary. Compliance with EU Regulation 2019/6 requires that veterinary oral powders for reconstitution be manufactured under GMP and that product information include the exact reconstitution volume and in-use shelf life; batch documentation is retained under EU GMP Annex 11. The terminal finished product is a dry powder for oral suspension for dogs and cats, supplied in 100 mL and 200 mL bottles after reconstitution volumes.

When Intramammary Ointment Bases Release Cefalexin Below the Teat Cistern pH after Milking

In lactating dairy cattle, cefalexin monohydrate is processed into sterile intramammary pastes or ointments where the active is suspended in an oleaginous or combined oily-aqueous vehicle. A representative formulation contains cefalexin monohydrate equivalent to 200 mg cefalexin per 10 g syringe, corresponding to 2.0% w/w active as cefalexin; the particle size of the API is reduced to D90 ≤ 20 μm by jet milling or high-shear wet milling with a sterile surfactant such as polysorbate 80. The vehicle is sterilized by moist heat at 121 °C for 15 min, but the active is added aseptically because cefalexin monohydrate degrades under saturated steam conditions. Aseptic filling into pre-sterilised single-use intramammary syringes is performed in a Grade A zone over Grade B background according to EU GMP Annex 1; sterility testing follows Ph. Eur. 2.6.1, and bacterial endotoxin control follows Ph. Eur. 2.6.14. The terminal product is a sterile intramammary suspension for lactating cows with a milk withdrawal period assigned by the national competent authority; residue depletion in milk is monitored using the authorised MRL approach rather than a fixed universal withdrawal period.

Cefalexin is not active against methicillin-resistant Staphylococcus aureus or beta-lactamase-producing Gram-negative mastitis pathogens; the product should not be used as monotherapy for culture-negative mastitis unless farm-level susceptibility data support it. Syringeability is measured as extrusion force at 20 °C; a force above 40 N indicates vehicle thickening and may cause incomplete udder infusion in cold conditions. The oleaginous base is formulated to have thixotropic yield stress sufficient to suspend micronized cefalexin during terminal sterilization and shipment; free oil separation greater than 5% by volume after standing at 25 °C for 7 days indicates a failed batch because dose uniformity cannot be guaranteed at the point of infusion.

Veterinary hospital pharmacies that extemporaneously compound cefalexin capsules from bulk API operate under a different control envelope than licensed manufacturers. Cefalexin monohydrate is geometrically diluted with lactose monohydrate or microcrystalline cellulose to produce capsules of 75 mg, 125 mg, 250 mg, and 500 mg cefalexin; the active proportion ranges from 10% w/w in low-strength capsules to 75% w/w in high-strength capsules when a 1000 mg capsule is used. In the United States, extralabel use of cephalosporins in food-producing species is restricted under 21 CFR 530.41; therefore compounded capsules from this pathway are directed to companion animal patients only. Batch-size limits and beyond-use dating follow the non-sterile compounding framework of USP <795> or the applicable national standards; the API is tested for identity, assay, and water content before compounding, and the final capsules are checked for mass uniformity under USP <905>.

Compounding is performed at 20–25 °C and 35–45% RH; powder is passed through a 0.3 mm sieve before trituration. A powder drum blender or manual geometric trituration is used until homogeneity is demonstrated by active content uniformity; the blended powder is filled into two-piece hard gelatin capsules using a semi-automatic capsule filling machine with tamping pins adjusted to achieve the required fill volume. Bulk API is stored in a tightly closed container protected from moisture because exposure above the validated relative humidity boundary produces tackiness and assay loss. This compounding pathway is intended for individual companion animals under veterinarian supervision; it is not a substitute for a licensed veterinary medicinal product where one exists.

Medicated Oral Premix: Physical Segregation of Cefalexin in Low-Inclusion Feed Blends

Where authorized for oral administration to calves, piglets, or poultry, cefalexin monohydrate is supplied as a medicated premix or oral powder for incorporation into milk replacer, drinking water, or dry feed. Premixes are manufactured to contain 10% w/w cefalexin activity on a lactose monohydrate or dextrose carrier; the API is serially diluted in a low-shear ribbon blender or conical screw blender, with mixing time fixed by blend uniformity studies according to Ph. Eur. 2.9.40. Demixing risk is controlled by matching particle-size distribution between carrier and active; the cefalexin fraction is milled to D90 ≤ 180 μm and the carrier is selected with bulk density between 0.60 g/mL and 0.75 g/mL. A representative oral powder for drinking water may contain 20% w/w cefalexin activity in a soluble matrix; however, published data for specific cefalexin water medication configurations in food-producing species are more limited than for companion animal formulations, and local marketing authorization restrictions or withdrawal periods must be consulted. Compliance with EU Regulation 2019/6 and applicable national medicated feed rules is required; cross-contamination prevention follows approved site protocols for beta-lactam antibiotics.

Dry filling into multi-wall paper-aluminium sacks with a polyethylene inner liner is conducted below 40% RH; the beta-lactam ring is susceptible to hydrolysis in aqueous media, so drinking water solutions should be prepared daily and not stored beyond 24 h, particularly when water pH exceeds 8.5 or when ambient temperature exceeds 25 °C. Terminal product types are medicated premix and oral powder for use in calves, piglets, and poultry only where a national marketing authorization or veterinary prescription pathway exists.